We are live on
!
Find out more
VM
VHCP Management Portfolio holdings
AUM
$93M
1-Year Est. Return
10.04%
This Fund
S&P 500
This Quarter
Est. Return
+6.48%
1 Year Est. Return
-10.04%
3 Year Est. Return
+233.99%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$223M
AUM Growth
+$35.4M
(+19%)
Cap. Flow
+$30.9M
Cap. Flow
% of AUM
13.9%
Top 10 Holdings %
Top 10 Hldgs %
88.92%
Holding
19
New
2
Increased
2
Reduced
2
Closed
1
Avg Time Held
2.8
quarters
Top 10 Avg Time Held
2.8
quarters
Top 20 Avg Time Held
2.8
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Adverum Biotechnologies
ADVM
|
+$41.1M |
| 2 |
Lipocine
LPCN
|
+$3.86M |
| 3 |
STML
Stemline Therapeutics, Inc.
STML
|
+$874K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KERX
Keryx Biopharmaceuticals Inc
KERX
|
+$10.8M |
| 2 |
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
|
+$7.47M |
| 3 |
ALXA
Alexza Pharmaceuticals Inc
ALXA
|
+$674K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 64.27% |
| 2 | Miscellaneous | 35.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
DELISTED
Adverum Biotechnologies
ADVM
| $42.8M | 19.25% |
+138,274
| New | +$41.1M |
2014 Q3
0 quarters
|
|
|
ANAC
2
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $28.8M | 12.96% |
1,178,474
-367,525
| -24% | -$7.47M |
2013 Q2
5 quarters
|
|
|
GWPH
3
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $25.2M | 11.33% |
311,853
| – | – |
2013 Q2
5 quarters
|
|
|
DYAX
4
DELISTED
DYAX CORPORATION
DYAX
| $20.2M | 9.1% |
2,000,859
| – | – |
2013 Q2
5 quarters
|
|
5
BioCryst Pharmaceuticals
BCRX
$2.18B
| $17.1M | 7.67% |
1,744,356
| – | – |
2013 Q2
5 quarters
|
|
6
DELISTED
Radius Health, Inc.
RDUS
| $11M | 4.95% |
525,000
| – | – |
2014 Q2
1 quarter
|
|
7
Larimar Therapeutics
LRMR
$277M
| $10M | 4.5% |
45,123
| – | – |
2014 Q2
1 quarter
|
|
8
Heron Therapeutics
HRTX
$77.1M
| $9.13M | 4.1% |
1,095,734
| – | – |
2013 Q3
4 quarters
|
|
|
AVDL
9
DELISTED
Avadel Pharmaceuticals
AVDL
| $7.16M | 3.22% |
500,000
| – | – |
2014 Q1
2 quarters
|
|
10
Neurocrine Biosciences
NBIX
$14.5B
| $4.76M | 2.14% |
303,503
| – | – |
2013 Q2
5 quarters
|
|
|
11
Lipocine
LPCN
$14.2M
| $4.09M | 1.84% |
39,407
+31,048
| +371% | +$3.86M |
2014 Q2
1 quarter
|
|
12
TherapeuticsMD
TXMD
$23.8M
| $3.93M | 1.77% |
16,930
| – | – |
2013 Q4
3 quarters
|
|
|
ZSPH
13
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
| $3.92M | 1.76% |
100,000
| – | – |
2014 Q2
1 quarter
|
|
14
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
| $3.46M | 1.55% |
1,193
| – | – |
2014 Q2
1 quarter
|
|
|
OCRX
15
DELISTED
Ocera Therapeutics, Inc.
OCRX
| $3.45M | 1.55% |
703,730
| – | – |
2013 Q4
3 quarters
|
|
|
STML
16
DELISTED
Stemline Therapeutics, Inc.
STML
| $884K | 0.4% |
+71,000
| New | +$874K |
2014 Q3
0 quarters
|
|
|
ALXA
17
DELISTED
Alexza Pharmaceuticals Inc
ALXA
| $166K | 0.07% |
71,212
-176,600
| -71% | -$674K |
2013 Q2
5 quarters
|
|
|
KERX
18
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| – | – |
-700,273
| Closed | -$10.8M | – |
|
Similar funds
QGI
KC
RSCM
ZC
TF
SAM
NA
NCIM
VHCP Management's Q3 2014 Portfolio in Review
As of Q3 2014, VHCP Management held 19 positions worth $223M, up 19% from $187M the previous quarter. Its ten largest holdings account for 89% of the portfolio.
VHCP Management deployed $30.9M of net new capital in Q3 2014, opening 2 new positions and adding to 2 existing holdings. Its largest new stake was Adverum Biotechnologies: 138,274 shares worth $42.8M.
By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 66% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was ANACOR PHARMACEUTICALS INC COM, an estimated $7.47M trimmed.
- VHCP Management's largest Q3 2014 buy was Adverum Biotechnologies: 138,274 shares worth $42.8M.
- VHCP Management added most to Lipocine in Q3 2014, an estimated $3.86M increase.
- VHCP Management's biggest Q3 2014 reduction was ANACOR PHARMACEUTICALS INC COM, cutting an estimated $7.47M.
- VHCP Management fully exited Keryx Biopharmaceuticals Inc in Q3 2014, selling an estimated $10.8M.
- VHCP Management's ten largest holdings make up 89% of its $223M portfolio in Q3 2014.
- VHCP Management opened 2 new positions and closed 1 in Q3 2014.
- VHCP Management's portfolio value rose 19% quarter-over-quarter to $223M.
Based on VHCP Management's 13F filing for Q3 2014, filed 13 Nov 2014.